First-line pembrolizumab plus chemotherapy versus chemotherapy alone for advanced esophageal cancer: 5-year extended follow-up in the Japanese subgroup of KEYNOTE-590
- DOI
- 10.1007/s10388-026-01200-8
- Published
- 2026-04-28
- Container
- Esophagus
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1007/s10388-026-01200-8,
title = {First-line pembrolizumab plus chemotherapy versus chemotherapy alone for advanced esophageal cancer: 5-year extended follow-up in the Japanese subgroup of KEYNOTE-590},
author = {Ken Kato and Takashi Kojima and Hiroki Hara and Akihito Tsuji and Hisateru Yasui and Kei Muro and Taroh Satoh and Naoyoshi Yatsuzuka and Tomoko Sakata and Shirong Han and Toshihiko Doi},
year = {2026},
journal = {Esophagus},
doi = {10.1007/s10388-026-01200-8},
url = {https://doi.org/10.1007/s10388-026-01200-8}
}RIS
TY - JOUR TI - First-line pembrolizumab plus chemotherapy versus chemotherapy alone for advanced esophageal cancer: 5-year extended follow-up in the Japanese subgroup of KEYNOTE-590 AU - Ken Kato AU - Takashi Kojima AU - Hiroki Hara AU - Akihito Tsuji AU - Hisateru Yasui AU - Kei Muro AU - Taroh Satoh AU - Naoyoshi Yatsuzuka AU - Tomoko Sakata AU - Shirong Han AU - Toshihiko Doi PY - 2026 JO - Esophagus DO - 10.1007/s10388-026-01200-8 UR - https://doi.org/10.1007/s10388-026-01200-8 ER -
APA
Kato, K., Kojima, T., Hara, H., Tsuji, A., Yasui, H., Muro, K., Satoh, T., Yatsuzuka, N., Sakata, T., Han, S., & Doi, T. (2026). First-line pembrolizumab plus chemotherapy versus chemotherapy alone for advanced esophageal cancer: 5-year extended follow-up in the Japanese subgroup of KEYNOTE-590. Esophagus. https://doi.org/10.1007/s10388-026-01200-8
Source records
- crossref · retrieved 2026-09-26T09:15:28.802Z